Search
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease … [L64052] It is used to identify tau NFT pathology in adults with cognitive impairment being evaluated for Alzheimer's disease and has not been established for evaluating non-Alzheimer's tauopathies.
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalNalbuphine is the only opioid analgesic that is not a controlled substance in the United States. … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Categories: Heterocyclic Compounds with 4 or More Rings, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriolBetrixaban
go.drugbank.com/drugs/DB12364ApprovedBetrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks … Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708].
Synonyms: N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamideTipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalTipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.
Butalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitThere have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acidSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigationalnot candidates for multiagent systemic therapy. … [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are
Dydrogesterone
go.drugbank.com/drugs/DB00378ApprovedInvestigationalWithdrawnUnlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation. … A synthetic progestational hormone with no androgenic or estrogenic properties.
Colfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawn[A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990. … Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigationalArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.